Meeting
2017 ASCO Annual Meeting
Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial.
Authors
Ilaria Colombo
Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada
Ilaria Colombo , Scott Lien , Cindy Yang , Derek L. Clouthier , Luisa Bonilla , Sunu Cyriac , Josee-Lyne Ethier , Yeh Chen Lee , Yada Kanjanapan , Victoria Mandilaras , Neesha C. Dhani , Marcus O. Butler , Amit M. Oza , Judy Quintos , Helen Chow , Trevor John Pugh , Pamela S Ohashi , Lillian L. Siu , Stephanie Lheureux
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT02644369
Citation
J Clin Oncol 35, 2017 (suppl; abstr 5581)
DOI
10.1200/JCO.2017.35.15_suppl.5581
Abstract #
5581
Poster Bd #
403
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.
First Author: Shuhang Wang
Poster
2018 ASCO Annual Meeting
Phase II (INSPIRE) trial of pembrolizumab (pembro) with serial immune and genomic profiling in patients (pts) with metastatic triple negative breast cancer (mTNBC).
First Author: Zachary William Neil Veitch
Poster
2018 ASCO Annual Meeting
Immune profiling in a randomized phase II trial of acalabrutinib and pembrolizumab (PA) versus pembrolizumab (P) for patients with metastatic urothelial cancer (mUC).
First Author: Tian Zhang
Poster
2018 ASCO-SITC Clinical Immuno-Oncology Symposium
Genomic and immune landscape of metastatic melanoma (MM) treated with pembrolizumab (PEM).
First Author: Yada Kanjanapan